VivoSeq
Oncology

Juvenile Myelomonocytic Leukemia

22

Pipeline Programs↗

2

Active Trials↗

14

Companies Involved↗

Juvenile Myelomonocytic Leukemia is an emerging landscape with 22 programs across 14 companies. The most active players are Alnylam Pharmaceuticals, Sanofi, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

67/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 1Sanofi logo

Sanofi

2 programs

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2V

Veloxis Pharmaceuticals

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

21 of 24 classified programs — the dominant modality here.

13%ALL OTHERSProtein / enzyme28%Cell therapy14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.

Analysis

Trial Status

9

clinical trials

Completed4 · 44%
Terminated2 · 22%
Active, not recruiting1 · 11%
Unknown status1 · 11%
Recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT05849662·58 enrolled
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03190915·10 enrolled
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
Completed·Children's Oncology Group·Phase 2·NCT01824693·30 enrolled
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Completed·National Cancer Institute (NCI)·Phase 2·NCT00025038·100 enrolled
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00167219·15 enrolled
Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT02447666·28 enrolled
Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00509600·1 enrolled
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00609739·1 enrolled
Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia
Unknown status·—·N/A·NCT03687463·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)